APA (7th ed.) Citation

Holmen, S., Manintveld, O., Damman, K., Braun, O., Löfman, I. H., Szymanski, M., . . . Lund University, P. a. a. o. s. r. e. (2026). DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial. American Heart Journal, 291, 128-135. https://doi.org/10.1016/j.ahj.2025.08.010

Chicago Style (17th ed.) Citation

Holmen, Stine, et al. "DAPAgliflozin for Renal Protection in Heart Transplant Recipients. Rationale and Design of the Randomized Controlled DAPARHT Trial." American Heart Journal 291 (2026): 128-135. https://doi.org/10.1016/j.ahj.2025.08.010.

MLA (9th ed.) Citation

Holmen, Stine, et al. "DAPAgliflozin for Renal Protection in Heart Transplant Recipients. Rationale and Design of the Randomized Controlled DAPARHT Trial." American Heart Journal, vol. 291, 2026, pp. 128-135, https://doi.org/10.1016/j.ahj.2025.08.010.